Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxil Bio (TSE:VXL)
:VXL
Holding TSE:VXL?
Track your performance easily
VXL Stock Chart & Stats
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.03
Previous CloseN/A
Volume4.43K
Average Volume (3M)0.00
Market Cap
C$684.89K
Enterprise Value-C$108.11K
Total Cash (Recent Filing)$1.02M
Total Debt (Recent Filing)$84.00K
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding136,978,970
10 Day Avg. Volume0
30 Day Avg. Volume0
Standard Deviation0.63
R-Squared0.07
Alpha0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vaxil Bio News
PremiumCompany Announcements
Vaxil Bio and Green Data Centers Terminate AgreementPremiumCompany Announcements
Vaxil Bio Announces Strategic Acquisition of Green Data Centers
PremiumCompany Announcements
Vaxil Bio Announces Potential Reverse Takeover
PremiumCompany Announcements
Vaxil Bio Advances Cancer Research Post-Takeover TerminationOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
VXL FAQ
What was Vaxil Bio’s price range in the past 12 months?
Vaxil Bio lowest stock price was <C$0.01 and its highest was C$0.03 in the past 12 months.
What is Vaxil Bio’s market cap?
Vaxil Bio’s market cap is C$684.89K.
When is Vaxil Bio’s upcoming earnings report date?
Vaxil Bio’s upcoming earnings report date is Apr 24, 2025 which is in 95 days.
How were Vaxil Bio’s earnings last quarter?
Vaxil Bio released its earnings results on Nov 27, 2024. The company reported C$0 earnings per share for the quarter, the consensus estimate of N/A by C$0.
Is Vaxil Bio overvalued?
According to Wall Street analysts Vaxil Bio’s price is currently Overvalued.
Does Vaxil Bio pay dividends?
Vaxil Bio does not currently pay dividends.
What is Vaxil Bio’s EPS estimate?
Vaxil Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio have?
Vaxil Bio has 136,978,970 shares outstanding.
What happened to Vaxil Bio’s price movement after its last earnings report?
Vaxil Bio reported an EPS of C$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaxil Bio?
Currently, no hedge funds are holding shares in TSE:VXL
---
Company Description
Vaxil Bio
Vaxil Bio Ltd is an immuno-oncology biotechnology company. It is principally engaged in research and development of the ImMucin vaccine to treat cancer. ImMucin is the company's immunotherapy product. The organization is focused on developing novel immunotherapies including neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. Its VaxHit platform allows identification, isolation, and production of specific antigen-based immunotherapy products.
---
Resverlogix
―
Medmira
―
Reliq Health Technologies
―
Waverley Pharma
―
Biocure Technology Inc
―
---